| Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess T Lindmo, E Boven, F Cuttitta, J Fedorko, PA Bunn Jr Journal of immunological methods 72 (1), 77-89, 1984 | 1128 | 1984 |
| Effect of low-intensity physical activity and moderate-to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy … H Van Waart, MM Stuiver, WH van Harten, E Geleijn, JM Kieffer, ... J Clin Oncol 33 (17), 1918-1927, 2015 | 674 | 2015 |
| Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer MB de Ruiter, L Reneman, W Boogerd, DJ Veltman, FSAM Van Dam, ... Human brain mapping 32 (8), 1206-1219, 2011 | 363 | 2011 |
| Late effects of high‐dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging MB de Ruiter, L Reneman, W Boogerd, DJ Veltman, M Caan, G Douaud, ... Human brain mapping 33 (12), 2971-2983, 2012 | 293 | 2012 |
| Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized … SF Duijts, M van Beurden, HS Oldenburg, MS Hunter, JM Kieffer, ... J Clin Oncol 30 (33), 4124-4133, 2012 | 253 | 2012 |
| Pretreatment Deoxycytidine Kinase Levels Predict in Vivo Gemcitabine Sensitivity JR Kroep, WJP Loves, CL Van Der Wilt, E Alvarez, I Talianidis, E Boven, ... Molecular cancer therapeutics 1 (6), 371-376, 2002 | 249 | 2002 |
| Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity NP van Erp, K Eechoute, AA van der Veldt, JB Haanen, AK Reyners, ... J Clin Oncol 27 (26), 4406-12, 2009 | 237 | 2009 |
| Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. K Mross, P Maessen, WJ Van Der Vijgh, H Gall, E Boven, HM Pinedo Journal of Clinical Oncology 6 (3), 517-526, 1988 | 226 | 1988 |
| Breast cancer classification by proteomic technologies: current state of knowledge SW Lam, CR Jimenez, E Boven Cancer treatment reviews 40 (1), 129-138, 2014 | 200 | 2014 |
| Development and molecular characterization of a 2′, 2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780 VWTR Van Haperen, G Veerman, S Eriksson, E Boven, APA Stegmann, ... Cancer research 54 (15), 4138-4143, 1994 | 199 | 1994 |
| Sunitinib for treatment of advanced renal cell cancer: primary tumor response AAM Van der Veldt, MR Meijerink, AJM van den Eertwegh, A Bex, ... Clinical Cancer Research 14 (8), 2431-2436, 2008 | 198 | 2008 |
| Beta-glucuronidase-mediated drug release M Graaf, E Boven, HW Scheeren, HJ Haisma, HM Pinedo Current pharmaceutical design 8 (15), 1391-1403, 2002 | 198 | 2002 |
| Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib AAM van der Veldt, MR Meijerink, AJM van den Eertwegh, JBAG Haanen, ... British journal of cancer 102 (5), 803-809, 2010 | 172 | 2010 |
| Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival H van Cruijsen, AAM van der Veldt, L Vroling, D Oosterhoff, ... Clinical Cancer Research 14 (18), 5884-5892, 2008 | 167 | 2008 |
| Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method RWF Van Leeuwen, EL Swart, E Boven, FA Boom, MG Schuitenmaker, ... Annals of oncology 22 (10), 2334-2341, 2011 | 155 | 2011 |
| CPT‐11 in human colon‐cancer cell lines and xenografts: characterization of cellular sensitivity determinants WJM Jansen, B Zwart, STM Hulscher, G Giaccone, HM Pinedo, E Boven International journal of cancer 70 (3), 335-340, 1997 | 150 | 1997 |
| Schedule dependence of sensitivity to 2′, 2′-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and … VWTR Van Haperen, G Veerman, E Boven, P Noordhuis, JB Vermorken, ... Biochemical pharmacology 48 (7), 1327-1339, 1994 | 147 | 1994 |
| Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1α protein by the oxidative stressor arsenite MCA Duyndam, TM Hulscher, D Fontijn, HM Pinedo, E Boven Journal of Biological Chemistry 276 (51), 48066-48076, 2001 | 142 | 2001 |
| EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models HR Hendriks, PE Pizao, DP Berger, KL Kooistra, MC Bibby, E Boven, ... European Journal of Cancer 29 (6), 897-906, 1993 | 142 | 1993 |
| Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer AAM van der Veldt, E Boven, HH Helgason, M van Wouwe, J Berkhof, ... British journal of cancer 99 (2), 259-265, 2008 | 140 | 2008 |
